Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells

Kidney International

Volumn 70, Issue 10, 2006, Pages 1725-1734

  Patzer, L ^a,b,c   Hernando, N ^b   Ziegler, U ^b   Beck Schimmer, B ^b   Biber, J ^b   Murer, H ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Ifosfamide; NaPi IIa; Renal Fanconi syndrome; Tubulopathy

Indexed keywords

CYCLOPHOSPHAMIDE; IFOSFAMIDE; MESSENGER RNA; SODIUM PHOSPHATE COTRANSPORTER;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; KIDNEY CELL; KIDNEY DISEASE; MEMBRANE TRANSPORT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNTHESIS;

ACETALDEHYDE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL TRANSPORT; CELL DEATH; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; IFOSFAMIDE; KIDNEY; MESNA; OPOSSUMS; PHOSPHATES; PHOSPHORAMIDE MUSTARDS; RNA, MESSENGER; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIA;

EID: 33750598303     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001803     Document Type: Article

References (57)

1. Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatr Nephrol 1999; 13: 153-162.
2. Skinner R, Cotterill SJ, Stevens MCG. Risk factors for nephrotoxicity after Ifosfamide treatment in children: a UKCCSG Late Effects Group study. Br J Cancer 2000; 82: 1636-1645.
3. Rossi R. Nephrotoxicity of Ifosfamide-moving towards understanding the molecular mechanisms [editorial]. Nephrol Dial Transplant 1997; 12: 1091-1092.
4. Goren MP. Oral MESNA: a review. Semin Oncol 1992; 19: 65-71.
5. Siu LL, Moore MJ. Use of MESNA to prevent Ifosfamide-induced urotoxicity. Support Care Cancer 1998; 6: 144-154.
6. Lauterburg BH, Nguyen T, Hartmann B et al. Depletion of total cysteine, glutathione, and homocysteine in plasma by Ifosfamide/MESNA therapy. Cancer Chemother Pharmacol 1994; 35: 132-136.
7. Aleksa K, Matsell D, Krausz K et al. Cytochrome P450 3A and 2B6 in the developing kidney: implications for Ifosfamide nephrotoxicity. Pediatr Nephrol 2005; 20: 872-885.
8. Kerbusch T, de Kraker J, Keizer HJ et al. Clinical pharmacokinetics and pharmacodynamics of Ifosfamide and its metabolites. Clin Pharmacokinet 2001; 40: 41-62.
9. Kaijser GP, DeKraker J, Bult A et al. Pharmacokinetics of Ifosfamide and some metabolites in children. Anticancer Res 1997; 18: 1941-1949.
10. Dechant KL, Brogden RN, Pilkington T et al. Ifosfamide/MESNA. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991; 42: 428-467.
11. Zamlauski Tucker MJ, Morris ME, Springate JE. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat-kidney. Toxicol Appl Pharmacol 1994; 129: 170-175.
12. Springate JE. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 1997; 17: 75-79.
13. Springate J, Chan K, Lu H et al. Toxicity of Ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In vitro Cell Dev Biol-Anim 1999; 35: 314-317.
14. Mohrmann M, Ansorge S, Schmich U et al. Toxicity of Ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture. Pediatr Nephrol 1994; 8: 157-163.
15. Dubourg L, Taniere P, Cochat P et al. Toxicity of chloroacetaldehyde is similar in adult and pediatric kidney tubules. Pediatr Nephrol 2002; 17: 97-103.
16. Mohrmann M, Pauli A, Walkenhorst H et al. Effect of Ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture. Ren Physiol Biochem 1993; 16: 285-298.
17. Scheinman SJ. X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney Int 1998; 53: 3-17.
18. Lloyd SE, Pearce SHS, Fisher SE et al. A common molecular basis for three inherited kidney stone diseases. Nature 1996; 379: 445-449.
19. Steinmeyer K, Schwappach B, Bens M et al. Cloning and functional expression of rat CLC-5, a chloride channel related to kidney disease. J Biol Chem 1995; 270: 31172-31177.
20. Schwake M, Friedrich T, Jentsch TJ. An internalization signal in ClC-5, an endosomal Cl- channel mutated in Dent's disease. J Biol Chem 2001; 276: 12049-12054.
21. Wang SS, Devuyst O, Courtoy PJ et al. Mice lacking renal chloride channel, CLC-5, are a model for Dent's disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum Mol Genet 2000; 9: 2937-2945.
22. Piwon N, Gunther W, Schwake M et al. ClC-5Cl(-)-channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 2000; 408: 369-373.
23. Devuyst O, Christie PT, Courtoy PJ et al. Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent's disease. Hum Mol Genet 1999; 8: 247-257.
24. Gunther W, Luchow A, Cluzeaud F et al. ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl Acad Sci 1998; 95: 8075-8080.
25. Ford MGJ, Pearse BMF, Higgins MK et al. Simultaneous binding of Ptd Ins(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science 2001; 291: 1051-1055.
26. Norden AGW, Lapsley M, Igarashi T et al. Urinary megalin deficiency implicates abnormal tubular endocytic function in Fanconi syndrome. J Am Soc Nephrol 2002; 13: 125-133.
27. Murer H, Hernando N, Forster I et al. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80: 1373-1409.
28. Tenenhouse HS, Sabbagh Y. Novel Pi regulating genes in the pathogenesis of renal Pi wasting disorders. Eur J Physiol 2002; 444: 317-336.
29. Murer H, Hernando N, Forster I et al. Regulation of Na/Pi transporter in the proximal tubule. Ann Rev Physiol 2003; 65: 531-542.
30. Bruggemann SK, Kisro J, Wagner T. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res 1997; 57: 2676-2680.
31. Borner K, Kisro J, Bruggemann SK et al. Metabolism of Ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Drug Metab Dispos 2000; 28: 573-576.
32. Pfister MF, Ruf I, Stange G et al. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc Natl Acad Sci 1998; 95: 1909-1914.
33. Pearcey R, Calvert R, Mehta A. Disposition of Ifosfamide in patients receiving Ifosfamide infusion therapy for the treatment of cervical carcinoma. Cancer Chemother Pharmacol 1988; 22: 353-355.
34. Goren MP, Wright RK, Pratt CB et al. Dechloroethylation of Ifosfamide and neurotoxicity. Lancet 1986; 2: 1219-1220.
35. Kerbusch T, vanPutten JWG, Groen HJM et al. Population pharmacokinetics of Ifosfamide and its 2-and 3- dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients. Cancer Chemother Pharmacol 2001; 48: 53-61.
36. Pinkerton CR, Rogers H, James C et al. A phase II study of Ifosfamide in children with recurrent solid tumors. Cancer Chemother Pharmacol 1985; 15: 258-262.
37. Boddy AV, Yule SM, Wyllie R et al. Pharmacokinetics and metabolism of Ifosfamide administered as a continuous infusion in children. Cancer Res 1993; 53: 3758-3764.
38. Wright JE, Elias A, Tretyakov O et al. High-dose Ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol 1995; 36: 345-351.
39. Boddy AV, Yule SM, Wyllie R et al. Intrasubject variation in children of Ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol 1996; 38: 147-154.
40. Yule SM, Price L, Pearson ADJ et al. Cyclophosphamide and Ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res 1997; 3: 1985-1992.
41. Yule SM, Price L, Cole M et al. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol 2001; 47: 222-228.
42. Sood C, O'Brien JP. Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem Pharmacol 1993; 46: 1621-1626.
43. Dubourg L, Michoudet C, Cochat P et al. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of Ifosfamide. J Articles Support Null 2001; 12: 1615-1623.
44. Broadhead CL, Walker D, Skinner R et al. Differential cytotoxicity of Ifosfamide and its metabolites in renal epithelial cell cultures. Toxicol In Vitro 1998; 12: 209-217.
45. Highley MS, Schrijvers D, vanOosterom AT et al. Activated oxazaphosphorines are transported predominantly by erythrocytes. Ann Oncol 1997; 8: 1139-1144.
46. Ullrich KJ, Rumrich G, David C et al. Bisubstrates - substances that interact with both, renal contraluminalorganic cation-transport systems. Pflugers Arch 1993; 425: 300-312.
47. Sladek NE, Doeden D, Powers JF et al. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 1984; 68: 1247-1254.
48. Kohn KW, Hartley JA, Mattes WB. Mechanisms of DNA-sequence selective alkylation of guanine-N7 Positions by nitrogen mustards. Nucleic Acids Res 1987; 15: 10531-10549.
49. Dong Q, Barsky D, Colvin ME. A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5′-d(GAC). Proc Natl Acad Sci 1995; 92: 12170-12174.
50. Springer JB, Colvin ME, Colvin OM et al. Isophosphoramide mustard and its mechanism of bisalkylation. J Org Chem 1998; 63: 7218-7222.
51. Boal JH, Williamson M, Boyd VL et al. P-31-Nmr studies of the kinetics of bisalkylation by isophosphoramide mustard - comparisons with phosphoramide mustard. J Med Chem 1989; 32: 1768-1773.
52. Patzer L, Ringelmann F, Kentouche K et al. Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial. Bone Marrow Transplant 2001; 27: 319-327.
53. +/Pi cotransporters. J Biol Chem 1997; 272: 20125-20130.
54. Denizot F, Lang R. Rapid colorimetric assay for cell-growth and survival - modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271-277.
55. Reshkin SJ, Forgo J, Murer H. Functional asymmetry of phosphate transport and its regulation in opossum kidney cells: phosphate transport. Pflugers Arch 1990; 416: 554-560.
56. Sorribas V, Markovich D, Hayes G et al. Cloning of a Na/Pi cotransporter from opossum kidney cells. J Biol Chem 1994; 269: 6615-6621.
57. Sorribas V, Markovich D, Werner A et al. Expression of Na/Pi cotransport from opossum kidney cells in Xenopus laevis oocytes. Biochim Biophys Acta 1993; 1178: 141-145.